Free scoping read. A written assessment of your manuscript in two business days, at no cost.

Start one

Call for papersCardiometabolic and liver disease

Call for Papers: Treatment and management of MASH/MASLD (BMC Medicine)

BMC Medicine’s collection addresses the treatment and management of metabolic dysfunction-associated steatotic liver disease, including MASH. This guide sets out topic areas consistent with that scope, fit checks for manuscripts and points to confirm before submission.

Pubrica InsightsEditorial team, reviewed by a subject specialist
Deadline
29 January 2027
Last checked
10 November 2026
Reading time
5 min
Sources
1
Submit through the official call

Key dates

Manuscript deadline
29 January 2027
Details last checked
10 November 2026
Open the official call

About the journal

Journal
BMC Medicine
Publisher
BMC, part of Springer Nature
Call type
Call for papers
Scope
Metabolic dysfunction-associated steatotic liver disease.
Guest editors
Listed on the official collection page
Access and fees
Open access; an article processing charge normally applies on acceptance
Originality
Original work, not under review elsewhere; confirm on the official page

Topics consistent with the call

  • Trials of pharmacological therapies for MASH and metabolic dysfunction-associated steatotic liver disease
  • Lifestyle, dietary and weight-loss interventions for patients with MASLD
  • Studies examining non-invasive tests for staging fibrosis and monitoring treatment response
  • Management of cardiometabolic comorbidities in people with MASLD
  • Models of care, referral pathways and screening in primary and specialist settings
  • Mechanistic and translational studies informing new treatment targets in MASH

Based on the published scope; the full list of themes is on the official call page.

Is your work a fit? Check before you write

  1. The manuscript addresses treatment or management of MASLD or MASH, not only its epidemiology.
  2. Diagnostic criteria and terminology are stated clearly, including how earlier definitions were handled.
  3. The study has broad clinical or public health relevance, consistent with BMC Medicine’s general medical scope.
  4. Outcomes are clinically meaningful and the study follows the relevant reporting guideline.
  5. The work is complete, approved by all co-authors and ready to submit before the stated deadline.

Why This Call Is a Priority Now

Metabolic dysfunction-associated steatotic liver disease is closely linked to obesity and type 2 diabetes, and the move to new nomenclature has renewed attention on its metabolic basis. Treatment options and approaches to identifying patients at risk of progression are developing, raising questions about selection, monitoring and integration with cardiometabolic care. A themed collection in a general medical journal brings this evidence to clinicians beyond hepatology and allows readers to compare therapeutic and service-level approaches.

Who Should Submit

Academic backgrounds

  • Hepatology and gastroenterology
  • Endocrinology and diabetes
  • Nutrition and obesity medicine
  • Clinical epidemiology
  • Primary care

Institutions and sectors

  • Academic hospitals and liver units
  • Universities and clinical research centres
  • Pharmaceutical and diagnostics companies
  • Primary care networks and health services

Article types commonly published in BMC Medicine

  • Clinical trials and other interventional studies
  • Observational studies
  • Systematic reviews and meta-analyses
  • Translational and mechanistic research

What the Editors Typically Value

  1. Interventional evidence on therapies or lifestyle approaches with clinically meaningful liver or cardiometabolic outcomes.
  2. Studies that clarify which patients are most likely to benefit from treatment or closer monitoring.
  3. Evaluations of care pathways that integrate liver disease management with wider metabolic care.
  4. Translational work identifying mechanisms that could inform new treatment strategies.

Paper Ideas You Could Develop

Risk-stratified care pathwayAn evaluation of a primary care pathway using non-invasive fibrosis tests to identify patients with MASLD for specialist referral.
Weight-loss interventions and liver outcomesA systematic review and meta-analysis of lifestyle and pharmacological weight-loss interventions on histological or imaging markers of MASH.
Monitoring treatment responseA cohort study assessing how changes in non-invasive markers relate to clinical outcomes in treated patients.

Your Plan to the Deadline

A suggested schedule working back from 29 January 2027. Adjust it to the stage your work has reached.

  1. By 15 Dec 2026

    Open the official collection page and the BMC Medicine submission guidelines; confirm the scope, article types and guest editors.

  2. By 29 Dec 2026

    Write a one-paragraph statement of your research question, design and the contribution your paper makes to the collection.

  3. By 8 Jan 2027

    Complete the analysis and agree the key findings, figures and tables with your co-authors.

  4. By 19 Jan 2027

    Draft the full manuscript to the BMC Medicine article type and the relevant reporting guideline.

  5. By 24 Jan 2027

    Circulate the draft to co-authors and an independent reader; revise for clarity, accuracy and completeness.

  6. By 27 Jan 2027

    Complete final checks: formatting, references, declarations, data availability statement and cover letter.

  7. By 29 Jan 2027

    Submit through the journal’s online system, selecting the collection, after re-checking the official call page.

What you gain from publishing here

  • Publication in BMC Medicine, reaching readers working on this topic.
  • A themed collection that groups your paper with related work.
  • Editorial and peer feedback that can strengthen the work, whatever the decision.
  • A peer-reviewed output for your CV, thesis or grant reporting.

What happens after you submit

  1. Submission: upload through the BMC Medicine online system and select the collection.
  2. Editorial screening: the editors check fit with the collection; papers outside its scope may be returned without review.
  3. Peer review: suitable papers are sent to reviewers under the journal’s review model.
  4. Revision and decision: respond to each reviewer comment and keep a record of the changes.
  5. Production: accepted papers move to proofs and open access publication, with the article processing charge set out by the publisher.

What the Collection Is Looking For

The collection is looking for research on how metabolic dysfunction-associated steatotic liver disease is treated and managed. Consistent with BMC Medicine’s remit, suitable work may include clinical trials and other interventional studies, observational studies, systematic reviews and meta-analyses, and translational or mechanistic research with clear clinical relevance. Authors should confirm accepted article types and any guest editor priorities on the official call page.

Read the call itselfThis guide summarises the call. Open the official collection page before you plan a submission, and record the date you checked it and the guest editors listed.Open the official call

Expert help

How Pubrica Can Help With This Submission

Pubrica’s subject specialists can review, write, edit, format and prepare your manuscript for this call, planned back from the deadline. You remain the author of your work.

Original research article writingManuscript writing from your data, structured to the journal’s article type and reporting guideline. Biostatistics and statistical programmingStatistical analysis plans, analysis, simulation code and statistical review of results. Systematic reviewProtocol, screening, data extraction and risk-of-bias assessment for review articles. Journal formattingFormatting of the manuscript, references, figures and tables to the journal’s guidelines. Cover letterA cover letter that explains how the manuscript fits the collection and the journal’s scope. Journal submissionPreparation of submission files and completion of the journal’s online submission system.
Go to the official call

FAQs

Questions Authors Ask

The published deadline is 29 January 2027. Collections can close early or be extended, so confirm the date on the official call page before you plan your submission.

The guest editors are listed on the official collection page. Check their research interests, as they help to judge whether your manuscript fits the collection.

It may, particularly if the authors explain how the population relates to current MASLD criteria. Clear reporting of diagnostic definitions is likely to help editors and reviewers. Authors should check the official call page for any guidance on terminology.

BMC journals publish articles open access, and an article processing charge normally applies on acceptance. Check the journal’s fees and funding page, and whether your institution has an agreement that covers the charge, before you submit.

Sources

  1. BMC Medicine. (2026). Treatment and management of MASH/MASLD [Collection call for papers]. BMC, part of Springer Nature. Retrieved 10 November 2026, from https://link.springer.com/collections/bhgbbbbidh

How to cite this page

Pubrica Insights. (2026). Call for Papers: Treatment and management of MASH/MASLD (BMC Medicine). Pubrica. https://pubrica.com/insights/calls-and-conferences/treatment-and-management-of-mash-masld/

  • MASLD
  • MASH
  • Liver disease
  • Cardiometabolic health
  • Hepatology

Other Open Calls

Closes 17 November 2026Organoids: connecting molecular insights and clinical practiceBMC Medicine Closes 30 November 2026New research in autismBMC Medicine Closes 7 December 2026Antibody-drug conjugates for cancer treatment: translational and clinical perspectivesBMC Medicine

All calls and conferencesPre-submission peer reviewAll Insights

Treatment and management of MASH/MASLD (BMC Medicine)Deadline 29 January 2027

Official call
Get a free quote

Regulations

Check your project against this rule

  1. 1Your work
  2. 2Your details
  3. 3Send
What do you need?

Material you send is held under signed confidentiality, with access limited to the assigned team and encrypted transfer. It is not used to train anything and is not passed to third-party tools. Ask for the agreement before you send anything you would rather cover first.